No headlines found.
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Business Wire (Fri, 13-Mar 4:05 PM ET)
Business Wire (Thu, 5-Mar 4:05 PM ET)
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference
Business Wire (Tue, 3-Mar 4:05 PM ET)
Contineum Therapeutics Inc is a clinical-stage biopharmaceutical company engaged in the development of oral small-molecule therapies for neurological, inflammatory, and immunological conditions. The company focuses on developing selective compounds targeting challenging molecular pathways and has built a portfolio of small molecule drug candidates. Its pipeline includes drug candidates in clinical development, such as PIPE-791, an LPA1 receptor antagonist being studied for idiopathic pulmonary fibrosis and chronic pain, and PIPE-307, an M1 receptor inhibitor being evaluated for relapsing-remitting multiple sclerosis and other depressive disorders.
Contineum Therapeutics trades on the NASDAQ stock market under the symbol CTNM.
As of April 6, 2026, CTNM stock price was flat at $13.44 with 122,088 million shares trading.
CTNM has a beta of 0.01, meaning it tends to be less sensitive to market movements. CTNM has a correlation of 0.00 to the broad based SPY ETF.
CTNM has a market cap of $490.96 million. This is considered a Small Cap stock.
Last quarter Contineum Therapeutics reported $0 in Revenue and -$.49 earnings per share. This fell short of revenue expectation by $-5 million and missed earnings estimates by -$.06.
The top ETF exchange traded funds that CTNM belongs to (by Net Assets): VTI, VXF, IBB, SCHA, IWC.
CTNM has outperformed the market in the last year with a price return of +98.2% while the SPY ETF gained +18.0%. CTNM has also outperformed the stock market ETF in the last 3 month and 2 week periods returning +18.0% and +11.0%, respectively, while the SPY returned -3.3% and +0.4%, respectively.
CTNM support price is $12.57 and resistance is $14.31 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that CTNM shares will trade within this expected range on the day.
